Trial Profile
An observational study evaluating treatment patterns and safety of safinamide in patients with Parkinson's disease in clinical practice
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms The SYNAPSES study
- 14 Jul 2017 New trial record
- 27 Jun 2017 Results from the feasibility evaluation of SYNAPSES presented at the 3rd Congress of the European Academy of Neurology
- 08 Jun 2017 Trial design presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.